GleamWall
中文EN

GNLX GENELUX Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1231457 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-95.3%
TTM net income YoY-5.6%
TTM EPS YoY18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-396,200.0%
Net margin-373,362.5%
FCF margin-270,112.5%
EBITDA margin-393,262.5%

Returns

ROE-130.6%
ROA-95.4%
ROIC (approx.)-180.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue4,762.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$0
R&D expense$6.91M$6.51M$5.78M$5.65M$4.74M$4.76M$4.70M$6.52M
SG&A expense$3.49M$3.14M$3.39M$3.77M$3.45M$3.03M$3.12M$3.23M
Operating income-$10.40M-$9.64M-$9.17M-$9.41M-$8.19M-$7.79M-$7.82M-$9.75M
Net income-$10.29M-$9.47M-$8.93M-$9.25M-$7.95M-$7.46M-$7.49M-$8.98M
EBITDA-$10.39M-$9.63M-$9.16M-$9.35M-$8.13M-$7.73M-$7.76M-$9.69M
EPS (basic)-0.23-0.21-0.20—-0.21-0.20-0.21—
EPS (diluted)-0.23-0.21-0.20—-0.21-0.20-0.21—
Weighted avg. shares (diluted)45.31M44.96M44.15M—37.89M37.95M34.93M—
Balance sheet
Cash & equivalents$9.45M$9.18M$9.27M$5.33M$4.69M$6.55M$16.21M$8.56M
Short-term investments$1.00M$9.50M$16.90M—$16.22M$21.43M$18.90M$22.33M
Current assets$10.93M$19.14M$26.75M$15.13M$21.55M$29.23M$35.95M$31.55M
PP&E, net$7.32M$4.60M$3.08M$2.17M$1.79M$1.34M$1.29M$1.32M
Total assets$20.61M$26.20M$32.37M$19.03M$24.99M$32.25M$38.98M$34.72M
Current liabilities$9.40M$8.00M$7.27M$6.22M$5.13M$6.99M$7.69M$6.90M
Total liabilities$11.43M$10.09M$9.45M$7.48M$6.40M$8.35M$9.14M$8.44M
Shareholders' equity$9.18M$16.11M$22.92M$11.54M$18.59M$23.90M$29.85M$26.27M
Shares outstanding45.49M45.10M44.84M38.14M38.05M37.76M37.73M34.73M
Cash flow statement
Operating cash flow-$5.93M-$6.44M-$6.06M-$6.20M-$6.58M-$7.06M-$5.43M-$4.30M
Capital expenditure$2.72M$1.53M$921,000$436,000$517,000$115,000$30,000$96,000
Free cash flow-$8.65M-$7.98M-$6.98M-$6.63M-$7.09M-$7.17M-$5.46M-$4.40M
Investing cash flow$5.78M$5.97M-$8.54M$6.56M$4.72M-$2.65M$3.51M$6.67M
Financing cash flow$409,000$387,000$18.54M$276,000$0$52,000$9.57M$91,000
Depreciation & amortization$10,000$10,000$9,000$60,000$61,000$62,000$59,000$57,000
Stock-based compensation$2.94M$2.27M$1.39M$1.53M$2.63M$1.48M$1.42M$1.43M

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.